• Pharmacotherapy · Apr 2013

    Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.

    • Sean M Barclay, Meghan N Jeffres, KimChi Nguyen, and Tamdan Nguyen.
    • College of Pharmacy, Roseman University of Health Sciences, Henderson, Nevada 89104, USA. sbarclay@roseman.edu
    • Pharmacotherapy. 2013 Apr 1;33(4):375-82.

    Study ObjectiveTo determine whether pharmacologic prophylaxis for venous thromboembolism (VTE) was associated with a decrease in the incidence of VTE or an increased incidence of bleeding in patients with chronic liver disease (CLD).DesignSingle-center, retrospective cohort analysis.SettingUniversity medical center.PatientsA total of 1581 adults with CLD hospitalized over a 3-year period for longer than 24 hours.Measurements And Main ResultsMedical records were reviewed for the primary outcome of VTE and documented episodes of bleeding during hospitalization and were divided into two groups based on receipt of pharmacologic VTE prophylaxis. During the 1581 hospitalizations, 392 (24.7%) patients received pharmacologic VTE prophylaxis. The incidence of VTE in the prophylaxis group was 0.5% compared with 1.8% in patients without prophylaxis (p=0.05). Documented bleeding rates were lower in the prophylaxis group (2.0% vs 10.3%, p<0.001). Multivariate logistic regression identified active malignancy (odds ratio [OR] 8.76, 95% confidence interval [CI], 2.56-29.58), trauma or surgery during hospitalization (OR 10.29, 95% CI 1.18-89.51), and history of VTE (OR 26.48, 95% CI 6.93-101.16) as risk factors of VTE. Use of pharmacologic VTE prophylaxis was protective against VTE (OR 0.34, 95% CI 0.04-0.88).ConclusionPharmacologic VTE prophylaxis was associated with a decreased incidence of VTE in patients with CLD without an increased rate of bleeding and should be routinely considered on admission to the hospital. Patients with CLD and active malignancy, trauma or surgery during hospitalization, or history of VTE appear to be at highest risk of VTE and thus warrant pharmacologic prophylaxis. Prospective studies must validate these findings.© 2013 Pharmacotherapy Publications, Inc.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.